10 Stocks Investors Are Watching Closely This Week

Ten companies capped off the trading week with strong double-digit gains, bucking a broader market bloodbath triggered by ongoing tensions in the Middle East that have sent oil prices soaring.

On Friday, Wall Street’s main indices all finished in the red, led by the Nasdaq, down 1.59 percent, followed by the S&P 500, losing 1.33 percent, and the Dow Jones, dropping 0.95 percent.

In this article, we spotlight the 10 top-performing companies last week and break down the reasons behind their gains.

To come up with the list, we focused on the companies with a $2 billion market capitalization and 5 million shares in trading volume.

The companies were picked based on the percentage growth in their prices on March 6 and February 27.

10. Samsara Inc. (NYSE:IOT)

Samsara saw its share prices jump by 22 percent week-on-week as investors took heart from the company’s path to profitability, having nearly wiped out its losses last fiscal year.

In an updated report, Samsara Inc. (NYSE:IOT) said that it narrowed its net losses by 94 percent to just $9 million in the fiscal year ending January 31, from a $155 million net loss a year earlier.

The strong performance was supported by a 28 percent jump in revenues during the period, at $1.6 billion versus $1.25 billion year-on-year.

In the fourth quarter alone, Samsara Inc. swung to a net income of $22 million, reversing a net loss of $11.2 million in the same quarter a year earlier. Revenues increased by 28 percent to $444.3 million from $346 million year-on-year.

“Fiscal year 2026 was an outstanding year of durable and efficient growth,” Samsara Inc. CEO Sanjit Biswas said, adding that the performance was driven by the scale of its data asset, which now captures more than 25 trillion data points annually to fuel its AI-powered platform.

For the first quarter of fiscal year 2027, the company is targeting to generate revenues of $454 million to $456 million, or an implied growth of 24 percent year-on-year.

For the full fiscal 2027 alone, revenues are expected to grow between 21 and 22 percent to a range of $1.965 billion to $1.975 billion year-on-year.

9. The Trade Desk Inc. (NASDAQ:TTD)

The Trade Desk jumped by 22.9 percent week-on-week as investors gobbled up shares following reports that it sealed a deal with OpenAI to sell advertisements on ChatGPT.

According to reports, OpenAI is setting its sights on advertising as it eyes generating further revenues beyond subscription and enterprise.

It targets to book $25 billion in revenues from advertising alone.

OpenAI was said to have begun ad trials last month through partnerships with advertising technology providers to support the effort.

Following the report, investment research firm Evercore ISI reiterated its “outperform” rating for The Trade Desk Inc. (NASDAQ:TTD), alongside a price target of $35.

According to Evercore, generative AI engines could represent a significant source of incremental gross spend relative to The Trade Desk Inc.’s $13.4 billion gross spending.

In other news during the week, The Trade Desk Inc. told the Securities and Exchange Commission that its president and chief executive officer, Jeff Green, raised his stake in the company through the acquisition of $148 million in shares from March 2 to 4, 2026. The shares were bought at prices ranging from $23.49 to $25.08 apiece.

8. Intapp Inc. (NASDAQ:INTA)

Intapp saw its share prices jump by 23.98 percent week-on-week despite ending Friday’s session in the red, as investor sentiment was primarily boosted by its ongoing AI adoption efforts to support its goal of hitting $1 billion in revenues over the next three years.

At a recently concluded annual conference in New York City, Intapp Inc. (NASDAQ:INTA) unveiled an agentic AI platform called Celeste, an expert colleague for businesses to help them automate and orchestrate core processes.

According to Intapp Inc., Celeste is programmed to be able to interact with humans and other agents, leverage a firm’s proprietary knowledge, execute firm-specific methodology and best practices, and honor strict compliance and confidentiality standards.

It is also able to analyze thousands of data points, screen deals, and flag complex conflicts, among others.

Celeste aside, Intapp Inc. also inked multiple deals with technology companies such as Microsoft, Anthropic, and Harvey to bolster its AI adoption.

In the second quarter of fiscal 2026, ending December 31, it grew its total revenues by 16 percent to $140 million from $121 million in the same period a year earlier, supporting a 42 percent narrower net loss at $5.9 million versus $10.2 million year-on-year.

7. Venture Global Inc. (NYSE:VG)

Venture Global grew its share prices by 28.8 percent week-on-week, with investor sentiment boosted by a flurry of positive developments, including strong earnings, a win in a legal battle, a rating upgrade, and its upcoming dividends.

Earlier in the week, the New York Supreme Court upheld its decision backing Venture Global Inc. (NYSE:VG) in relation to its legal battle filed by oil giant Shell Plc, allegedly for its improper sale of liquefied natural gas.

Shell had already lost the battle in August 2025, but challenged the ruling in November.

Following the news, investment firm Goldman Sachs issued a “buy” recommendation for Venture Global Inc., alongside a price target of $15, saying that the court ruling was a key milestone for the latter.

In other developments, Venture Global Inc. also announced a strong earnings performance last year, with net income attributable to shareholders surging by 53.7 percent to $2.26 billion from $1.47 billion in 2024. Revenues soared by 177 percent to $13.77 billion from $4.97 billion year-on-year.

In the fourth quarter alone, net income attributable to shareholders increased by 22 percent to $1.067 billion from $871 million, while revenues nearly tripled to $4.4 billion from $1.5 billion in the same comparable period.

Following the results, the company said that it would distribute dividends amounting to $0.018 per share to all holders of Class A and B stocks as of March 16, 2026, payable on March 31.

6. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)

Iovance soared by 32.9 percent week-on-week to hit a new all-time high after an analyst doubled its price target for the stock, while investors loaded portfolios ahead of business updates next week.

In its market report, investment firm UBS raised its price target for Iovance Biotherapeutics Inc. (NASDAQ:IOVA) to $4 from $2 previously, but maintained a “neutral” stance on its stock.

The coverage came ahead of the biopharmaceutical firm’s participation in Barclays’ 28th Annual Global Healthcare Conference on Wednesday, March 11, where investors will watch out for cues and company developments to support buying appetite.

In other news, Iovance Biotherapeutics Inc. recently reported a 5 percent wider net loss last year, at $390.98 million versus $372 million in 2024. Total revenues, on the other hand, jumped by 60.6 percent to $263.5 million from $164.07 million year-on-year.

Earlier in the week, Wix.com Ltd. (NASDAQ:WIX) said that its revenues soared to $1.99 billion last year from $1.76 billion in 2024, thanks to a double-digit growth in revenues from creative subscriptions and business solutions.

However, net income still decreased by 63 percent to $50.6 million from $138.3 million year-on-year.

In the fourth quarter alone, Wix.com Ltd. said that revenues surged by 14 percent to $524.3 million from $460.4 million. However, it swung to a net loss of $40.2 million from a $48 million net income in the same period.

For this year, the company is targeting revenues to grow by mid-teens in both the first quarter and full-year period.

Bookings are also expected to grow mid-teens in the full-year period.

Following the results, Wix.com Ltd. announced plans to go aggressive and quick on its share buyback program this year, as it eyes to already complete majority of its $2 billion share repurchase authorization.

As of end-2025, the company has already bought back $575 million worth of shares.

4. Tango Therapeutics Inc. (NASDAQ:TNGX)

Tango Therapeutics soared by 52.15 percent week-on-week, as investors took heart from a flurry of positive developments, including a “buy” recommendation for its stock and the start of a series of clinical trials for its pancreatic cancer treatment candidate vopimetostat..

In a market report during the week, investment firm Stifel reaffirmed its “buy” recommendation and $15 price target for Tango Therapeutics Inc. (NASDAQ:TNGX), following improvements in its earnings performance last year, having narrowed its net losses by 22 percent to $101.59 million from $130.3 million in 2024.

Total revenues, on the other hand, jumped by 48.3 percent to $62.38 million from $42.07 million year-on-year.

However, net loss in the fourth quarter widened by 26 percent to $38.7 million from $30.76 million, having earned no revenues during the period, versus a $5.4 million revenue in the same period a year earlier.

For this year, Tango Therapeutics Inc. is targeting to kick off a number of clinical trials to test its drug candidate vopimetostat in combination with multiple inhibitors for the treatment of pancreatic cancer.

It recently clinched a partnership with Erasca to jointly study the combination of vopimetostat with ERAS-0015 in treating pancreatic cancer.

3. Amprius Technologies Inc. (NYSE:AMPX)

Amprius Technologies rallied by 52.19 percent week-on-week and hit a new all-time high after a flurry of positive developments, including analyst upgrades and a highly optimistic outlook for the year.

In separate market reports, Cantor Fitzgerald and Craig-Hallum raised their price targets for Amprius Technologies Inc. (NYSE:AMPX) to $20 and $21, from $16 and $17, respectively.

Cantor issued an “overweight” rating while Craig-Hallum assigned a “buy” recommendation.

The coverage followed Amprius Technologies Inc.’s highly optimistic outlook for this year, having targeted a 71 percent growth in revenues for the full-year period.

According to the company, it is setting its sights on revenues of $125 million this year, versus $73 million last year. If realized, it would end the year with a 417-percent revenue jump in just two years, versus only $24.17 million in 2024.

However, it expects to remain at a net loss of $8 million in 2026, albeit an 82-percent expected improvement from $44 million in net losses last year.

“2025 marked a year of meaningful commercial progress, as we expanded our customer base to over 550, increased revenue by over 3x, and advanced the adoption of our silicon anode batteries across multiple end markets,” Amprius Technologies Inc. CEO Tom Stepien said.

“Growing demand from existing customers, new program wins, and improved execution across our manufacturing partners drove strong momentum throughout the year. Looking ahead to 2026, we plan to leverage our enhanced supply chain to scale production and meet accelerating market demand, supporting continued accretive growth,” he added.

2. Sable Offshore Corp. (NYSE:SOC)

Sable Offshore skyrocketed by 74 percent week-on-week, as investors placed bets following an executive department’s opinion confirming that President Donald Trump could override conflicting federal laws that prevent the listed firm from conducting full operations at its California pipeline system.

Thomas Elliot Gaiser, assistant attorney general for the Office of Legal Counsel of the Department of Justice, said that a presidential order could preempt California laws currently impeding Sable Offshore Corp. (NYSE:SOC) from fully operating its Las Flores onshore pipeline.

Operations at its offshore unit, Santa Ynez, have already started in May, but Sable Offshore Corp. remains unable to sell or transport hydrocarbons through its Las Flores unit pending court approval.

“We conclude that it (a presidential order) would. An order issued as an exercise of congressionally delegated authority or the President’s constitutional powers has the force of federal law under the Supremacy Clause and may preempt contrary state law,” he said.

“Because the DPA (Defense Production Act) authorizes the President to order certain actions that may otherwise be prohibited by state law, an order issued pursuant to the DPA could preempt those laws expressly or by conflict,” he noted.

The statement sparked renewed optimism and buying appetite for Sable Offshore Corp., which has been battling for the revival of the pipeline for 10 years since it was ordered shut in June 2015 following a leak that caused a major oil spill.

1. Day One Biopharmaceuticals Inc. (NASDAQ:DAWN)

Day One soared by 100 percent week-on-week, as investors gobbled up its shares following an acquisition that it is set to be taken private and tendered at a 68 percent upside.

In a statement earlier in the week, Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) said that it is set to be acquired by France-based Servier for a transaction worth $2.5 billion.

Under the agreement, all issued and outstanding shares of Day One Biopharmaceuticals Inc. will be tendered at $21.50 apiece, or a 68 percent upside from the $12.78 closing price prior to the announcement.

According to the companies, the transaction is expected to be closed in the second quarter of the year, subject to customary closing conditions, including shareholder approval.

“Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies make it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life-threatening diseases,” Day One Biopharmaceuticals Inc. CEO Jeremy Bender said.

“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma. Importantly, Servier’s dedication to the rare disease community preserves the patient‑first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve,” he noted.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.